Officer received an award of 162 IDXX derivative securities | OQRO Insider tradesWhy it stands out
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
All the details
Dates, kept separate
- Transaction date
- Feb 12, 2026
- Reporting period
- Not applicable
- Filed with the SEC
- Feb 18, 2026
OfficerGrant / award
Context
- Classification
grant award
Code A — grant or award
- Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
- Record ID
- 0000874716-26-000023
- Filed / recorded
Feb 18, 2026, 12:30 AM UTCAdded to OQROOct 2, 2026, 12:28 PM UTC Data qualityVerified: identifiers matched exactly IssuerIDEXX LABORATORIES INC /DE Reporting personMichael Lane Officer titleExecutive Vice President SecurityIncentive Stock Option (right-to-buy) TableDerivative (Table II) Transaction dateFeb 12, 2026 Acquired / disposedAcquired (A) Footnotes from the filing
- Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2030.
Around the same time
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Idexx Laboratories's Executive Vice President sold $1.12M of Idexx Laboratories shares. Nobody planned it ahead of time.